CI

At a glance

ClinicalIndex Comparison Record
Phase 3Recruiting· 212 target
Drug / intervention
Toripalimab +2 moredrug
Likely dose
Toripalimab 240mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05340491
NCT05340491Phase 3RecruitingOn Track
Long Recruiting
CompareCT.gov

Chemoradiotherapy Combined With Programmed Death 1 Antibody in Recurrent Nasopharyngeal Carcinoma: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial

Sun Yat-sen University·interventional·Posted Apr 22, 2022·Updated May 11, 2026

In Brief

A Phase 3 clinical trial evaluating Toripalimab, Chemotherapy, and 1 other intervention for Nasopharyngeal Carcinoma. Currently recruiting, targeting 212 participants across 12 sites.

Detailed Summary

This is a multicenter, open-label, randomized, controlled, phase III trial. The purpose of this trial is to evaluate the efficacy and toxicity of anti-PD-1 antibody combined with chemoradiotherapy versus chemoradiotherapy alone in recurrent nasopharyngeal carcinoma patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNasopharyngeal Carcinoma
CountriesChina
Collaborators--

Timeline

Phase 3Recruiting
2023202420252026202720282029
First PostedApr 22, 2022
Enrollment StartApr 1, 2022
Primary CompletionDec 1, 2026
Study CompletionDec 1, 2028
TodayJul 1, 2026
Enrollment to primary: 4.7 yearsPosted 4.2 years agoPrimary completion in 5 months

Interventions

Toripalimabdrug

240mg, D1, every 3 weeks per cycle, three cycles with chemotherapy and eight cycles after IMRT

Chemotherapydrug

Gemcitabine: 1.0g/m2, D1 and D8, Cisplatin 80mg/m2, D1, every 3 weeks per cycle, total three cycles

Intensity modulated radiotherapyradiation

total 60-66Gy, 1.8-2.0Gy/f/day